May 1, 2016, A-share listed company Boji Pharmaceutical (300404.SZ) announced to launch a 300-million-Yuan sized Innovative Pharm Investment Fund with Shenzhen Winning Innovative Capital, aimed to investment in equity of innovative pharm or company.  Boji Pharmaceutical (300404.SZ) is a leading domestic pharmaceutical CRO company covering pre-clinical, clinical trial service and R&D outsourcing service, while Shenzhen Innovative Capital is the subsidy of Winning Capital which is an emerging PE/VC firm expert in health industry investment. This VC+VRO business model is believed to be effective way in innovative pharm investment which can significantly reduce the information asymmetric during the project valuation of innovative pharm pipelines, thanks to the reliable test result from CRO company. Innovative pharm investment is always the Peal on the Crown with countless ten-baggers and even hundred-baggers, while the high threshold of huge input, long period and low success rate keep many fund at a distance. However, the opportunity is on the way since the traditional wealth pathway of pharm manufacturing is become narrower and narrower along with the encouraging CFDA policy and better capital preference is beating the new door of industry transition and promotion.